Personalis, Inc., in collaboration with professor Charles Swanton and his colleagues at London’s Francis Crick Institute and University College London, published new results from their TRACERx lung cancer study in Nature Medicine.
Two new studies led by researchers at Washington University School of Medicine in St. Louis have identified a possible way to block the progression of several forms of blood cancer using a drug already in clinical trials against breast cancer.
A recent population-based study indicates that among children with cancer, those with obesity at the time of diagnosis may face an elevated risk of dying. The findings are published by Wiley online in CANCER.
UC Davis Comprehensive Cancer Center researcher Sanchita Bhatnagar and her team have been working to get to the bottom of the genetic determinants of the racial disparity in triple-negative breast cancer.Â
Scientists at City of Hope identified a protein that could help prevent CAR T-cell therapy antigen escape. The research, published in the journal Cell, could lead to more personalized therapies that improve cancer patients’ survival.
A little-known mouse protein disrupts cancer-causing chemical changes to genes associated with human colorectal cancer cells and potentially could be used to treat solid tumors, according to a new study from researchers at the Johns Hopkins Kimmel Cancer Center and the Chinese Academy of Sciences.
The phase III PATINA trial demonstrated that the addition of Ibrance (palbociclib) to current standard-of-care first-line maintenance therapy (following induction chemotherapy) resulted in statistically significant and clinically meaningful improvement in progression-free survival by investigator assessment in patients with hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer.Â
Johnson & Johnson announced positive topline results for overall survival from the phase III MARIPOSA study, evaluating Rybrevant (amivantamab-vmjw) plus Lazcluze (lazertinib) as a first-line therapy for patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions (ex19del) or L858R substitution mutations.Â
Elinzanetant successfully met the primary endpoints of the phase III trial OASIS 4 investigating elinzanetant as non-hormonal treatment for moderate to severe vasomotor symptoms caused by adjuvant endocrine therapy in women with breast cancer or at high risk of developing breast cancer, demonstrating statistically significant reductions in the frequency of moderate to severe vasomotor symptoms (also known as hot flashes) from baseline to week four and 12 compared to placebo.Â
A new phase III trial led by UCLA Health Jonsson Comprehensive Cancer Center investigators found that a diet low in omega-6 and high in omega-3 fatty acids, combined with fish oil supplements, significantly reduced the growth rate of prostate cancer cells in men with early-stage disease.
